Auxilium Pharmaceuticals — Investor Presentation (September 2009)
52 slides from Auxilium Pharmaceuticals's investor presentation, Sep 9, 2009
Slide 1: September 2009
September 2009 Exhibit 99.1 (NASDAQ: AUXL)
Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to market, size of market,
Slide 3: Focused on Sustainable Long-term Growth
Focused on Sustainable Long-term Growth XIAFLEX New Territories XIAFLEX New Indications XIAFLEX Peyronie’s XIAFLEX Dupuytren’s Testim
Slide 4: 2009 Milestones Achieved
• Completed enrollment in Peyronie’s Phase IIb (Feb. 2) • Filed BLA for Dupuytren's Contracture (Feb. 27) • Received FDA priority review (Apr. 28) and PDUFA Date (Aug. 28) • Secured $30 M Revolving Credit Line with Silicon Valley Bank (Aug. 4) • CORD I published in New England Journal of Medicine (S
Slide 5: Anticipated XIAFLEX Events 2009-2010
• FDA Arthritis Advisory Committee Meeting (September 16, 2009) • U.S. Dupuytren’s Contracture Launch (~ 60 days post-approval) • Top-line results of Peyronie's Phase IIb Study (4Q09) • Pfizer files MAA for Dupuytren’s Contracture in EU (2010) • Initiation of Peyronie's Phase III Studies (2010) Anti
Slide 6: Pipeline Continues to Advance
Pipeline Continues to Advance TESTIM ® GEL XIAFLEX™ XIAFLEX™ XIAFLEX™ Transmucosal Film AA4010 Transmucosal Film Transmucosal Film Hormone & Urology Note: Seeking partners for Transmucosal film product candidates PRODUCT LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III MARKET Hypogonadism Dupuy
Slide 7: Strong Strategic Partner for XIAFLEX in EU Validates Market Potential
Strong Strategic Partner for XIAFLEX in EU Validates Market Potential • Compelling economics for Auxilium: • Up-front payment of $75 million • $150 million tied to regulatory milestones • $260 million based on sales milestones • Significant increasing tiered royalties based on sales of XIAFLEX in Pf
Slide 8: XIAFLEX Driver of Long-Term Growth
XIAFLEX Driver of Long-Term Growth XIAFLEX product and packaging have not been approved by the FDA
Slide 9: XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity
XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity • Potential to be the only effective non-surgical treatment for two high unmet needs: – Dupuytren’s contracture – Peyronie’s disease • Well-characterized mode of action • State of the art biological manufacturing facility • Worldwide rights gener
Slide 10: Dupuytren's Contracture is Debilitating for Patients
Dupuytren’s Contracture is Debilitating for Patients • Excessive collagen deposition in fascia of hand • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Quality of life and daily activities can be significantly affected • Surgery may be rese
Slide 11: Current Treatment Options Require Invasive Surgery or Are Unapproved
Current Treatment Options Require Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective • Surgery • Non-surgical options > Splinting > Physical therapy > Corticosteroids • Needle fasciotomy/ aponeurotomy • Amputation
Slide 12: XIAFLEX Offers an Improved Mechanism of Action
XIAFLEX Offers an Improved Mechanism of Action • Clostridial collagenase is faster and more potent than human collagenase – Activity of XIAFLEX further enhanced by optimizing the ratio of collagenases in the product End products Fast cleavage Human collagenase Human collagenase (MMP) (MMP) Slow clea
Slide 13: CORD I - Largest Double-blind, Placebo-controlled Trial in Dupuytren's Contracture
CORD I - Largest Double-blind, Placebo- controlled Trial in Dupuytren’s Contracture rd • Primary endpoint is reduction in contracture to within 0 - of normal > randomized in 2:1 ratio of active to placebo > enrolled a 2:1 ratio of MP:PIP > enrolled 1:1 ratio of less severe to more severe joints • Se
Slide 14: Results Are Comparable to Surgery at the Joint Level
Results Are Comparable to Surgery at the Joint Level Hurst et al. NEJM 2009 Collagenase Placebo MP Joints (N=133) PIP Joints (N=70) P < 0.001 P < 0.001 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% XIAFLEX (N=203) Placebo (N=103) P < 0.001 MP = metacarpophal
Slide 15: Almost 100% of MP Joints and 2/3 of PIP Joints Achieved Better than 50% Improvement
Almost 100% of MP Joints and 2/3 of PIP Joints Achieved Better than 50% Improvement Hurst et al. NEJM 2009 MP = metacarpophalangeal PIP = proximal interphalangeal 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% XIAFLEX (N=203) Placebo (N=103) Collagenase Placebo MP Joints (N=133) PIP Joints (N=70) 100%
Slide 16: MP Joints Responded Better than PIP Joints
MP Joints Responded Better than PIP Joints, but PIP Joints Were More Severe at Baseline Hurst et al. NEJM 2009 79.3% reduction in contracture for XIAFLEX patients vs. 8.6% reduction for placebo patients (p<0.001) Baseline Last XIAFLEX (All Joints) (N=203) Placebo (N=103) MP Joints (N=133) PIP Joints
Slide 17: Greater Improvement in Range of Motion than Placebo
Treatment with XIAFLEX Resulted in Greater Improvement in Range of Motion than Treatment with Placebo 36.7 vs 4 P < 0.001 36.7 43.9 80.7 49.5 45.3 Collagenase Placebo Hurst et al. NEJM 2009 ° ° ° ° ° °
Slide 18: MP Joints Exhibited a Mean Improvement in Range of Motion
MP Joints Treated with XIAFLEX Exhibited a 41 Mean Improvement in Range of Motion Baseline 30 Days After Last Injection Mean values were rounded to the nearest whole number. Hurst et al. NEJM 2009
Slide 19: PIP Joints Exhibited a Mean Improvement in Range of Motion
PIP Joints Treated with XIAFLEX Exhibited a 29 Mean Improvement in Range of Motion Baseline 30 Days After Last Injection ° Mean values were rounded to the nearest whole number. Hurst et al. NEJM 2009
Slide 20: Early Intervention with XIAFLEX May Be the Most Effective Approach
Early Intervention with XIAFLEX May Be the Most Effective Treatment Approach MP Joints PIP Joints MP = metacarpophalangeal PIP = proximal interphalangeal 50 ° >50 ° 40 ° >40 ° Contracture at Baseline Hurst et al. NEJM 2009 88.9% (72/81) 57.7% (30/52) Less Severe More Severe 80.9% (17/21) 22.4% (11/4
Slide 21: XIAFLEX Was Well-Tolerated in the CORD I Study
XIAFLEX Was Well-Tolerated in the CORD I Study • Most adverse events were local reactions to injection or related to manipulation and rates were consistent with prior XIAFLEX trials • Most treatment related adverse events were mild or moderate in intensity and resolved without intervention within a
Slide 22: XIAFLEX is a Potential First-line Nonsurgical Option
XIAFLEX is a Potential, First-line Nonsurgical Option for Patients with Dupuytren’s Contracture • Efficacy should compare favorably to surgery – Primary endpoint of 5° for both MP and PIP joints reached with statistical significance in multiple studies – Secondary endpoints support commercial uptake
Slide 23: Phase III AE and SAE Rates Compare Favorably To Surgical Complications
XIAFLEX Phase III AE and SAE Rates Compare Favorably To Surgical Complications Tendon / Ligament: Confirmed Tendon Rupture 3 0.12% Ligament Injury 1 0.04% Total Tendon / Ligament 4 0.15% Deep Vein Thrombosis 1 0.04% Dupuytren’s Disease 1 0.04% Complex Regional Pain Syndrome 1 0.04% Total 7 0.27% • C
Slide 24: XIAFLEX Offers a Nonsurgical Treatment for Dupuytren's Contracture
XIAFLEX Offers a Nonsurgical Treatment for Dupuytren’s Contracture
Slide 25: XIAFLEX I.P. Position for Dupuytren's Contracture
XIAFLEX I.P. Position for Dupuytren’s Contracture • U.S. Orphan Drug granted on May 23, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity expected in EU for 10 years post-approval > Data protection granted for 8 years • Method of Use Patent in U.S. through 2014 • Use Patent in
Slide 26: XIAFLEX Supply Chain
XIAFLEX Supply Chain • API produced in Horsham, PA – 2 ° - 8 ° C storage expected at launch – Annual capacity at current yield should be sufficient for several years of global launch expectations – 1 manufacturing train in use and validated; capacity to expand for future demand • Fill and Lyophiliza
Slide 27: Dupuytren's Contracture – an Unmet Medical Need
Dupuytren’s Contracture –an Unmet Medical Need NEJM 2009 Hueston 1963 Skoog 1948 Mikkelsen 1976 Tubiana • Disease prevalence is estimated at 3%-6% of adult Caucasian population, or 13.5 to Million, in U.S. and EU, but occurs in all populations • Higher prevalence in patients of northern-European des
Slide 28: Extensive Market Research Performed with Dupuytren's Surgeons
Extensive Market Research Performed with Dupuytren’s Surgeons • Multiple prevalence data sets proved to be highly variable in numbers of patients • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture • A combined 571 Orthopedic Surgeo
Slide 29: Annually, >240,000 Dupuytren's Candidates Could Exist between U.S. & EU
Annually, >240,000 Dupuytren’s Candidates Could Exist between U.S. & EU Source: 2006 Auxilium research and analysis
Slide 30: Sustainable Blockbuster Market for Dupuytren's Contracture Anticipated
Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated • High disease prevalence – Based on literature, ~ 13.5M to 27M patients in U.S. and EU, however only ~ 1M patients annually seeking treatment in U.S. and EU • Sustainable patient pool – New patients within an ageing population •
Slide 31: Peyronie's Disease is a Devastating Disorder
Peyronie’s Disease is a Devastating Disorder Smith BH. Am J Clin Pathol . 1966;45:670-678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Symptoms > Pain with erection, penile curvature/ d
Slide 32: Peyronie's Disease - an Unmet Medical Need
Peyronie’s Disease - an Unmet Medical Need Schwarzer U, The prevalence of Peyronie’s disease: Results of a large survey. BJU Int 2001;88:727-30; Mulhall et al: J Urology 2004:171: 2350 - 2353;Rhoden et al: Int J. Impot Res 2001 :13 : 291 - 293; La Pera et al : EUR Urology 2001: 40 :525 - 530. Smith
Slide 33: Current Surgical Options - Treatment of Last Resort
Current Surgical Options- Treatment of Last Resort • The goal of surgery is simply to make the two sides of the penis equal in size through reduction of the longer side • Post-surgically, graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K • Patients are highly motivated to att
Slide 34: Unapproved Treatments for Peyronie's Disease Have Been Used With Little Reported Success
Unapproved Treatments for Peyronie’s Disease Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Energy transfer treatment including extracorporeal shock wave therapy (ESWT), laser a
Slide 35: Study 1030 / Study 1035
Study 1030 Percent of patients a-i-er Month 3 Month 6 Month 9 Study 1035 Tae : | Week6 Month3 Month6 Months a Innovations for tite”
Slide 36: Peyronie's Phase IIb Study Top-line Data Expected in 4Q09
Peyronie’s Phase IIb Study Top-line Data Expected in 4Q09 • Study designed to assess the safety and efficacy with XIAFLEX. – XIAFLEX will be administered two times a week every six weeks for up to three treatment cycles (2 x 3) – ~120 patients – 12 U.S. sites • Patients must be able to maintain a ri
Slide 37: Peyronie's Phase IIb Study Design
Peyronie’s Phase IIb Study Design A XIAFLEX yes 45 B Placebo yes 15 C XIAFLEX no 45 D Placebo no 15 120 Arm Study Drug Plaque Modeling Targeted Number of Patients • Patients will be randomized in a 3:1 ratio of XIAFLEX to placebo and a 1:1 ratio to receive penile plaque modeling or no modeling.
Slide 38: Peyronie's Phase IIb Trial Utilizes a Novel Patient Reported Outcome
Peyronie’s Phase IIb Trial Utilizes a Novel Patient Reported Outcome (PRO) • Study is designed to validate Auxilium’s proprietary Peyronie’s Patient Reported Outcome (PRO) questionnaire. • PRO will measure four domains of patients’ sexual quality of life, over a 36 week period: – penile pain – Peyro
Slide 39: Extensive Market Research Performed with Peyronie's Surgeons
Extensive Market Research Performed with Peyronie’s Surgeons • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease • A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and 383 have given fe
Slide 40: Annually, 210,000 Peyronie's Candidates Could Exist between U.S. and Europe
Annually , 210,000 Peyronie’s Candidates Could Exist between U.S. and Europe Source: 2006 Auxilium research and analysis
Slide 41: XIAFLEX I.P. Position for Peyronie's Disease
XIAFLEX I.P. Position for Peyronie’s Disease • U.S. Orphan Drug granted on March 12, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity in EU could be extended to 11 years on approval of additional indication • Method of Use Patent in U.S. through 2019 • Use Patent Granted in F
Slide 42: Testim 1% Testosterone Gel: Near-Term Growth Driver
Testim ® 1% Testosterone Gel: Near-Term Growth Driver
Slide 43: Testim Maintains Double-Digit Growth in Testosterone Replacement Therapy Market
Testim ® Maintains Double-Digit Growth in Testosterone Replacement Therapy Market *Mulligan T. et al. Int J. Clin Pract • Proprietary, topical 1% testosterone gel > Once-a-day application > Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45 yrs are hypogonad
Slide 44: 447% +30%
447% +30%
Slide 45: Gels Continue to Drive Significant Growth in TRT Marketplace
Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data $35 $117 $200 $287 $340 $383 $449 $690 $563 $49 $59 $77 $118 $210 $302 $399 $459 $499 $568 $685 $819 Gel Patch Oral Injectables ($ in millions) Gel Segment Growth ($) July 2009 L12M: 26.4%
Slide 46: Testim Quarterly Net Revenues and Scripts
Testim® Quarterly Net Revenues and Scripts Continuing Track Record of Consistent Revenue Growth ($ in millions) 2Q09 Net Testim Revenues Y/Y Growth: +26.8% 2Q09 TRX Y/Y Growth: +15.7% Source: Auxilium and IMS data $42.8M $68.9M $95.7M $125.1M $72.1M
Slide 47: Testim Patent Coverage
Testim Patent Coverage *Note: The referenced Testim patents are owned by CPEX Pharmaceuticals, Inc. U.S. • U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 • Divisional application and continuations filed with U.S. PTO in late 2007 with a plan t
Slide 48: FDA Has Granted Our Citizen's Petition In Part And Denied It In Part
FDA Has Granted Our Citizen's Petition In Part And Denied It In Part • Auxilium’s Citizen’s Petition was filed in February 2009 and FDA response was received in August 2009. • FDA has agreed with some of the statements we made in our Citizen's Petition regarding the testing required for generic vers
Slide 49: 1H '09 Financial Results and 2009 Guidance
Revenues $73.9 $58.0 $155-165 R&D Expense $27.2 $26.6 $45-50 SG&A Expense $55.8 $43.2 $120-130 Net Loss ($26.6) ($25.2) ($50-55) Stock – Based Comp Expense $9.4 $4.9 $16-19 Cash & Cash Equivalents $80.4 1H ‘09 Financial Results and 2009 Guidance ($ Millions) 1H ’09 1H ‘08 Guidance Currently approxim
Slide 50: Strategic Priorities in 2009 and 2010
Strategic Priorities in 2009 and 2010 • Obtain approval from the FDA in Dupuytren’s Contracture; • Execute a successful launch in the U.S. for XIAFLEX in Dupuytren’s contracture approximately 60 days after our approval date; • Complete enrollment in the observational long term follow up study of Dup
Slide 51: Focused on Sustainable Long-term Growth
Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories
Slide 52: Auxilium Management Contact
Auxilium Management Contact James E. Fickenscher/CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. (484) 321-5900 September 2009 (NASDAQ: AUXL) [email protected] [email protected]
Auxilium Pharmaceuticals — Investor Presentation (September 2009) on 6ix